LANSING, Mich., March 30, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is very pleased to report that scientists working in the Company’s sponsored research program at the University of Notre Dame have succeeded in significantly increasing the number and proportion of DNA insertions which yield transient expression of the Company’s targeted marker protein. “These results, which are occurring in the latest generation of genetic insertions performed in the laboratory, are very exciting, and we believe that it is further evidence that research team is on the right track” said CEO Kim K. Thompson.

The increase which the team is reporting is in both absolute numbers and in the percentage of insertions which ultimately result in the expression. This progress report from the laboratory follows the Company’s announcement of the achievement of a number of milestones over the last six months. “This is the first time we have seen the number of DNA insertions yielding transient expression reach the triple digits. We do seem to be in a state of acceleration in terms of the pace of laboratory achievement,” added Mr. Thompson.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops”, “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com